AI IntelligenceMar 3, 2026Primary Market
Article
Antiverse · $9.3M · Series A
UK-based biotech company Antiverse has closed a $9.3 million Series A round. The company uses AI to design therapeutic antibodies for hard-to-target disease targets. The round was led by Soulmates Ventures.
Data Cube AI EditorialSource: Tech.eu
01
Source Brief
UK-based biotech company Antiverse has closed a $9.3 million Series A round. The company uses AI to design therapeutic antibodies for hard-to-target disease targets. The round was led by Soulmates Ventures.
02